<DOC>
	<DOCNO>NCT03076372</DOCNO>
	<brief_summary>MM-310 liposomal formulation docetaxel prodrug target EphA2 receptor cancer cell . Docetaxel approve chemotherapeutic drug.This study Phase 1 open-label study MM-310 patient solid tumor . In first part study , MM-310 assess monotherapy maximum tolerate dose ( MTD ) establish . After MTD MM-310 monotherapy establish , expansion cohort MM-310 combination therapy assess .</brief_summary>
	<brief_title>A Study Evaluating MM-310 Patients With Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Must one follow cancer , patient either receive intolerant therapy know confer clinical benefit Urothelial carcinoma Gastric/gastroesophageal junction/esophageal carcinoma ( G/GEJ/E ) Squamous Cell Carcinoma Head neck ( SCCHN ) Ovarian cancer Pancreatic ductal adenocarcinoma ( PDAC ) Prostate adenocarcinoma ( PAC ) Nonsmall cell lung cancer ( NSCLC ) Small cell lung cancer ( SCLC ) Triple negative breast cancer ( TNBC ) Endometrial carcinoma Soft tissue sarcoma subtypes except GIST , desmoid tumor pleomorphic rhabdomyosarcoma Able provide inform consent , legal representative able willing ≥ 18 year age Availability cancerous lesion amenable biopsy willing undergo pretreatment biopsy ECOG Performance Status 0 1 Adequate bone marrow reserve evidence : ANC &gt; 1,500/µl ( unsupported growth factor ) Platelet count &gt; 100,000/µl Hemoglobin &gt; 9 g/dL Patients must adequate coagulation function evidence prothrombin time ( PT ) , activate partial thromboplastin time ( aPTT ) international normalize ratio ( INR ) within normal institutional limit Adequate hepatic function evidence : Serum total bilirubin ≤ ULN Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤ 2.5 x ULN . Alkaline phosphatase ≤ 2.5 x ULN , unless elevate alkaline phosphatase due bone metastasis . In case alkaline phosphatase &gt; 2.5 x ULN patient eligible inclusion aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤ 1.5 x ULN Adequate renal function evidence serum/plasma creatinine &lt; 1.5 x ULN Recovered effect prior surgery , radiotherapy antineoplastic therapy CTCAE v4.03 grade 1 , baseline less , except alopecia Women childbearing potential fertile men partner must willing abstain sexual intercourse use effective form contraception study 6 month follow last dose MM310 . Prior treatment docetaxel within 6 month study enrollment Pregnant lactating Treatment systemic anticoagulation ( e.g . warfarin , heparin , low molecular weight heparin , antiXa inhibitor , etc . ) except aspirin Any evidence hematemesis , melena , hematochezia , ≥ grade 2 hemoptysis , gross hematuria Any history hereditary bleeding disorder Presence active infection unexplained fever &gt; 38.5°C screen visit first schedule day dose , investigator 's opinion might compromise patient 's participation trial affect study outcome . At discretion investigator , patient tumor fever may enrol Known CNS metastases Known hypersensitivity component MM310 , docetaxel Prior treatment MM310 Received treatment , within 28 day 5 halflives , whichever short , prior first schedule day dose , investigational agent receive regulatory approval indication disease state prior clinically significant treatment related toxicity resolve Grade 1 baseline Received recent antitumor therapy include standard chemotherapy radiation within 14 day ( yet recover actual toxicity recent therapy ) prior first schedule dose MM310 Received anticancer drug know antiVEGF/VEGFR activity within period 5 halflives drug ( e.g . 100 day bevacizumab , 75 day ramucirumab ) prior first schedule dose MM310 Clinically significant cardiac disease , include : NYHA Class III IV congestive heart failure , unstable angina , acute myocardial infarction within six month plan first dose , arrhythmia require therapy ( include torsades de pointes , exception extrasystole , minor conduction abnormality , control well treat chronic atrial fibrillation ) Patients appropriate candidate participation clinical study reason deem investigator Patients receive organ allogeneic bone marrow peripheral blood stem cell transplant Chronic use corticosteroid 10mg daily prednisone equivalent past 4 week prior plan start MM310 Concomitant use strong inhibitor CYP3A Patients peripheral neuropathy grade 2 high</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Oncology</keyword>
	<keyword>Phase I</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>Carboplatin</keyword>
	<keyword>MM-310</keyword>
	<keyword>EphA2</keyword>
	<keyword>Ephrin A2</keyword>
	<keyword>Solid tumor</keyword>
	<keyword>urothelial carcinoma</keyword>
	<keyword>gastric carcinoma</keyword>
	<keyword>squamous cell carcinoma head neck</keyword>
	<keyword>ovarian cancer</keyword>
	<keyword>pancreatic ductal adenocarcinoma</keyword>
	<keyword>prostate adenocarcinoma</keyword>
	<keyword>non-small cell lung cancer</keyword>
	<keyword>small cell lung cancer</keyword>
	<keyword>triple negative breast cancer</keyword>
	<keyword>endometrial carcinoma</keyword>
	<keyword>soft tissue sarcoma</keyword>
	<keyword>Merrimack</keyword>
</DOC>